قالب وردپرس درنا توس
Home / Business / After the NIAID trial failed, Eli Lilly won a blockbuster deal for Covid-19 antibodies – Endpoints News

After the NIAID trial failed, Eli Lilly won a blockbuster deal for Covid-19 antibodies – Endpoints News



Two days after Eli Lilly admitted that its antibody bamlanivimab had failed in Covid-19 hospitalized patients, the U.S. government was preparing to sell it.

The pharmaceutical giant reported earlier on Wednesday that once it obtained the EUA seal from the FDA, the company reached an agreement to provide 300,000 bottles of the drug to the Federal Reserve at a price of $375 million. Once the two-month supply agreement is completed, the government can choose to purchase an additional 650,000 doses on the same terms, which may add $812 million.

The government is queuing to deliver a 700-mg dose of the drug, although a study pointed out by Eli Lilly aimed at proving efficacy emphasizes that the drug obtained from AbCellera cannot be used in recently diagnosed patients. On day 1

1, only the 2800 mg dose was effective for the primary endpoint, and from baseline changes in viral load, both high and low doses were meaningless-although even this is a dubious hypothesis.

Many analysts point out that Lilly’s data is moderate at best, and there is no dose-dependent response to help Lilly’s case. But Eli Lilly said that the data is close enough, and using a lower dose, they can get more doses in EUA applications.

Eli Lilly added that by the end of 2021, it has the capacity to produce 1 million doses of the drug and will increase its global supply in the first quarter. After the FDA took action, the first 100,000 vials could be used almost immediately.

Even if NIAID just concluded a study to test the drug in hospitalized patients, this is still a big possibility. The researchers ruled out security issues and opened the door for emergency authorization. Eli Lilly quickly issued a statement saying that researchers still believe that the drug can be used in patients with milder conditions, although this situation is based on their BLAZE-1 study, which showed that the 700 mg dose was ineffective.

David Ricks, Chief Executive Officer of Eli Lilly and Company, pointed out: “We believe that sambanibizumab may be an important treatment option that can bring value to the entire healthcare system because it has been shown to reduce the virus. Load, reduce symptoms and hospitalization rates, and thus have potential benefits for clinical outcomes.”


Source link